Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Sana Biotechnology Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $121.97, while Sana Biotechnology Inc trades at $3.68 (market cap $1.07B). The key difference: ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ARKQ | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $5.92 |
52-Week Low | $91.86 | $2.68 |
Market Cap | — | $1.07B |
Enterprise Value | — | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
